NTLA
Intellia Therapeutics, Inc. · Healthcare
Insiders bought $1.4M of Intellia Therapeutics, Inc. in the last 12 months
1 insider bought on 1 day.
NTLA over the last year
Largest buyers, last 12 months
NTLA after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Congress
Members reported 2 trades in NTLA since 2023.
Every filing
107 insider filings since 2016, newest first
John M Leonard · President and CEO
Edward J Dulac III · EVP and Chief Financial Officer
Michael P Dube · VP and Chief Accounting Officer
Edward J Dulac III · EVP and Chief Financial Officer
John M Leonard · President and CEO
Birgit C Schultes · EVP and Chief Scientific Officer
James Basta · EVP and General Counsel
Fred E Cohen · Director
David Lebwohl · EVP and Chief Medical Officer
Eliana Clark · EVP and Chief Technical Officer
Edward J Dulac III · EVP and CFO
Michael P Dube · VP and Chief Accounting Officer
John M Leonard · President and CEO
William J Chase · Director
Michael P Dube · VP and Chief Accounting Officer
Frank Verwiel · Director
James Basta · EVP and General Counsel
Laura Sepp-Lorenzino · EVP and Chief Scientific Officer
John M Leonard · President and CEO
David Lebwohl · EVP and Chief Medical Officer
Laura Sepp-Lorenzino · EVP and Chief Scientific Officer
Glenn Goddard · EVP and CFO
Derek Hicks · EVP and Chief Business Officer
James Basta · EVP and General Counsel
Eliana Clark · EVP and Chief Technical Officer
Muna Bhanji · Director
Eliana Clark · EVP and Chief Technical Officer
James Basta · EVP and General Counsel
John M Leonard · President and CEO
Laura Sepp-Lorenzino · EVP and Chief Scientific Officer
Derek Hicks · EVP and Chief Business Officer
David Lebwohl · EVP and Chief Medical Officer
Glenn Goddard · EVP and CFO
Eliana Clark · EVP and Chief Technical Officer
James Basta · EVP and General Counsel
John M Leonard · President and CEO
Laura Sepp-Lorenzino · EVP and Chief Scientific Officer
David Lebwohl · EVP and Chief Medical Officer
Glenn Goddard · EVP and CFO
David Lebwohl · EVP and Chief Medical Officer
David Lebwohl · EVP and Chief Medical Officer
John F Crowley · Director
John F Crowley · Director
David Lebwohl · EVP and Chief Medical Officer
Glenn Goddard · EVP and CFO
John M Leonard · President and CEO
Laura Sepp-Lorenzino · EVP and Chief Scientific Officer
David Lebwohl · EVP and Chief Medical Officer
Glenn Goddard · EVP and CFO
John M Leonard · President and CEO
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.